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The graft-versus-host reaction (GVHR) in both mice 
and humans can lead to the development of a broad 
spectrum of c linical and pathological symptoms. These 
symptoms are strikingly similar to those of a number of 
diseases of proven or presumed immunolog ical origin, 
such as systemic lupus erythematosus (SLE), other col-
lagen vascular diseases, lymphoproliferative disease, 
and aplastic anemia. 
The purpose of our investigation was to describe the 
immunological and pathological events that take place 
in the course of graft-versus-host disease (GVHD) and 
to gain insight into the cellular mechanisms underlying 
these events. To this end, a model was employed in which 
nonirradiated F, mice were used as recipients of paren-
tal lymphoid cells. By pathological manifestations, 2 
basic forms of GVHD can be distinguished in such non-
irradiated Ft recipients: One is acute GVHD which is 
often lethal. It is characterized b y a variety of suppres-
sive (hypoplastic) pathological symptoms, including a 
severe hypoplasia of the lymphohemopoietic system ac-
companied by aplastic anemia and hypogammaglobuli-
nemia. The other basic form is characterized by stimu-
latory symptoms, such as persistent lymphoid hyperpla-
sia, formation of autoantibodies, 'and development of 
pathological symptoms reminiscent of SLE and other 
collagen vascular diseases. The suppressive pathological 
graft-versus-host (GVH) symptoms are caused by T sup-
pressor/killer (T81K) cells of the donor which react to-
wards allogeneic class-1-structures of the F 1 recipient's 
major histocompatibility complex (MHC). The stimula-
tory pathological GVH symptoms, by contrast, are 
caused by donor T helper (T'') cells which react toward 
the recipient's allogeneic class-II-MHC structures. 
The possible implications of these observations for the 
pathogenesis of a number of GVH-like diseases in hu-
mans are discussed. The hypothesis is advanced that 
some of these GVH-like conditions, which arise either e 
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ANA: antinuclea r ant ibodies' 
DPH: diphenylhydantoin 
dsDNA: double-stranded DNA 
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GV HR: graft-versus- host reaction(s) 
ICGN: immune complex glomerulonephri t is 
MCH: major histocompatibi li ty complex 
MuLV: murine leukemia virus 
PLN: popli teal lymph node 
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TDTH cell : T cell causing delayed hyperse nsitivity reaction 
Tg: thyroglobu lin 
TH cell: T -helper cell 
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causa ignota or after exposure to certain viruses or 
drugs, are caused b y T lymphocytes reacting against 
self-MHC structures on lymphohemopoietic cells that 
were rendered "foreign". By analogy to GVHD, it is 
conceivable that the development of either stimulatory 
or suppressive GVH-like symptoms in individuals ex-
posed to a given virus or sensitizing drug depends not 
on the etiologic agent per se, but on whether the predom-
inant r esponse is made by the individual's TH or T 81K 
cells. This, in turn, might depend on whether the agent 
becomes immunogenic in combination with class-II or 
class-! alloantigens. 
Lymphocytes are highly specialized in recognizing and re-
sponding to foreign elements invading from the outside world 
while no apparent, or at least no harmful , immune reactions 
develop towards self-constituents. Previously, it had been pro-
posed t hat t his state of se lf-tolerance is achieved by del etion of 
self-reactive clones during ontogeny and autoimmunity results 
from the effect of "forbidden clones" [1] . From more recent 
experimental scrutiny, however, we know t hat potentially au-
toreactive B lymphocytes do exist in the intact, healthy immune 
system (2-8] but are normally controlled by mechanisms pre-
cluding autoimmune reactivity. The designation autoimmune 
disease is unambiguous where the functional relevance of auto-
antibodies to unaltered autoant igens has been establ ished, e.g., 
an t ibodies reacting with t he acetylcholine receptor in myas-
t henia gravis, with erythrocytes in autoimmune hemolytic ane-
mia, with t he insulin receptor in some patients with insulin -
resistant diabetes, with t hyroglobulin in Hashimoto's t hyroid-
itis, with basement membrane structures in Goodpasture's syn-
drome, with t he intrinsic factor in pernicious anemia, or with 
various autoant igens as in systemic lupus erythematosus 
(SLE). Other di sease processes are also immunologically me-
diated, a lt hough t hey are not strictly auto immune in t he sense 
that the immune reaction is directed to unal tered se lf-antigen. 
For instance , immune complexes t hat contain foreign materia l, 
such as microbial ant igens, can cause deleterious lesions such 
as glomerulonephri t is. Thus, in t his type of immunologica l 
disea e t he target antigens need not consist of unaltered se lf-
ant igens. Moreover, patients with aplastic anemia may have T 
lymphocytes that suppress t he growth of erythroid and myeloid 
colonies in cultures [9,10] . Here, the elicit ing antigen is not 
known at a ll. 
To analyze t he mechanisms of autoimmune diseases 2 gen -
era lly different types of experimental an imal models have been 
used: t hose in which t he diseases occur spontaneou.sly and those 
in which t he diseases are induced in recipients that usually 
would not suffer from autoimmune attacks. The spontaneous 
lupu~- like disease of New Zealand Black mice is an example of 
the l!rst type. Vanous tec hmques have been applied for t he 
e.xperi~ental induction of aut?immunity: t hese include injec-
t iOn of syngenetc or a llogenetc t issues mixed with Freund 's 
complete adjuva nt into normal animals, manipulation of the 
lymphocyte population by t hymectomy at a stage of immatu-
ri ty, or modification of normal cells by chemica ls and viruses. 
The present paper focuses first on the well -defined cellula r 
115s 
116s GLEICHMANN AND GLEICHMANN 
pathogenes is of a spectrum of immunologic diseases which can 
be induced by T lymphocytes in ge netica lly normal mice 
undergoing systemic graft-versus-host reactions (GVHR). In 
t his model T lymphocytes are responding to allogeneic struc-
tu res of t he major hi stocompat ibili ty complex (MHC) (i.e., H -
2) . The second part of the paper deal s with t he possible patho-
ge nic mechanism(s) of GVHR-like immunologic disorders 
which arise after exposure to a fore ign compound and might be 
due to graft-versus-host-(GVH) like reactions ofT lymphocytes 
towards self-structures rendered non -self by the etiologic agent. 
GRAFT-VERSUS-HOST REACTIONS (GVHR) 
Experimental Design 
GVHR was induced by injection of parental strain lympho-
cytes in to adult, otherwise untreated, F1 hybrid recipients. For 
genetic reasons, t he grafted cells are tolerated and not rejected 
by the semiallogeneic F, host. The injected T lymphocytes, 
however, recognize alloant igens which the F1 host has inherited 
from the other parental stra in . These a lloreactive donor T 
lymphocytes mediate the development of various immunologi-
cal lesions .' For t he induction of immunologic diseases by 
GVHR 2 conditions are required: 1) alloreactive T lymphocytes 
have to be present in t he inoculum and 2) a histoincompatibility 
has to be present in the F 1 recipient in order to activate the 
donor T lymphocytes. In non irradiated F, mice, the histoincom-
patibility has to be provided by t he recipient's major histocom-
patibility complex MHC, i.e., H -2 in t he mouse. 
Spec;l;rum of GVHR-Induced Immunological Disorders 
Fig 1A shows the spectrum of pat hological symptoms which 
can be induced by GVHR. The majority of t hese alterations 
han.: been obse rved as sequelae ofGVHR in both human (11,12] 
ana labo ratory animals (12- 14] . Two basic forms of GVHR-
in duced pathological lesions have been distinguished. One form 
is characte rized by stimulatory pathological symptoms, as shown 
in t he middle and on the left hand side of Fig lA . These 
sympto ms include a persistent lymphoid hyperplasia of mainly 
B lymphocytes resul t ing in hypergammaglobulinemia and the 
formation of autoantibodies characteristic of SLE, such as 
ant ibodies against nuclea r antigens (ANA), double-stranded 
DNA (dsONA), erythrocytes, and thymocytes [3,15- 20]. In 
addi t ion, s t imulatory GVH symptoms include a severe immune-
complex glomerulonephritis (ICG N) in which antibodies 
aga inst ANA and envelope antige ns of murine leukemia virus 
(MuLV) are involved (21]. This ICGN may be accompanied by 
deposition of immunoglobulin a long the basement membrane 
of t he skin [4]. The SLE-Iike GVH symptoms may occur 
together with symptoms characte ri stic of other collagen vas-
cula r diseases including a rteritis (15,22,231, chronic polyarthri -
t is [23 ], Sjogren- and sc leroderma-like lesions, and li ve r 
changes resembling sclerosing cholangitis (22,23]. Usually , t he 
stimulato ry GVH symptoms present themse lves as chronic 
GV H disease (G VHD). 
The other basic form of GVHR-induced lesions is character-
ized by suppressive (hypoplastic) pathological symp toms (see 
right hand side of Fig lA) which clini ca lly manifest themselves 
as an acute GVHR. The suppressive GVH symptoms consist 
of a seve re hypoplasia of the lympho-hemopoietic compartment 
leading to aplast ic anemia and hypoga mmaglobulinemia [18-
20,24,25]. The microb iologica l status of t he recipients bas an 
influence on whether or not t hi s form of GVHR will terminate 
as lethal GVHD . 
Subsets of Alloreactive T Lymphocytes Induce Either 
St imulatory or S uppressive GVHR Syndromes 
Severa l experimental approaches have been taken to analyze 
if functiona ll y different subsets of alloreactive donor T ce ll s 
are activated in the F1 rec ipients undergo ing different forms o[ 
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FIG l. Spectrum and concept of cellular pathogenesis of immuno· 
logical disorders resulting from GVHR in F, mice. Not listed is toxic 
epidermal necrolysis which is a serious GVH complication in species 
other than mouse, such as hamster and man (see [1 2] for references). 
A, Spectrum of pathological lesions that. may develop in GVH F, mice. 
B, Concept of the basic cellular and MHC requirements for induction 
of stimulatory and middle (left) and suppressive (right) GVHR lesions, 
respectively. The F1 cell depicted at the bottom represents a stimulator/ 
target cell situated at various anatomical sites, such as lympho-hemo-
poietic tissue, endothelium, synovia, skin, salivary gland, bile ducts, 
gut, and lungs. 
GVHD. One approach was to separate the donor T cells into 
Lyt subsets before transferring them into F, recipients. In a 
second approach unseparated T cell s were injected into F 1 
rec ipients differing only at class I and/or II H-2 antigens 
[17,18] . ln addition , in vitro studies were performed to dissect 
the ce llular and immunogenetic requirements of a llohelp and 
allosuppression [26]. Based on t he results of these experiments 
a general concept of the cellular pathogenesis ofG VHR-induced 
diseases has been elaborated, as illustrated in Fig lB. 
Thus, when the donor's Lyt 1+2- T-helper (TH) cells [19] are 
activated by class-ll MHC structures of the F, recipient per-
sistent lymphoid hyperplasia and SLE-like GVHD develop 
[1 7,18]. Whether t hese class-Il -reactive donor T cells also 
trigger the GVH-associated ma lignant lymphomas [14,27] and 
symptoms of co llage n vascular disease, such as chronic polyar-
t hritis, Sjogren- and scleroderma- like disease, has not yet been 
established. 
The cellular in teractions leading to suppressive pathological 
GVH symptoms are more complex. Optimal induction of the 
suppressive GVH symptoms required non -Lyt-separated donor 
T ce ll s [19] and incompatibility in the F, recipients at both 
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B. abnormal T-B cell cooperation (GVHR) 
@ 
·------®······ 
20. 
·. i 
.... ___ ·®··· .... 
3 0 
·------®····· 
4 0/. 
·------®··· ··· 
absence of 
antigen 
Tg 
t1 
absent or 
inadequate signal G): 
no cross-linking of 
lg receptors 
adequate signal G) : 
cross-linking of 
lg receptors 
FIG 2. Hypothesis showing essential differences between normal 
and abnormal T -8-cell cooperation in order to explain the selected 
autoantibody fo rmation seen in SLE- Iike GVHD. All B cells depicted 
here are unprimed; hence, their ave rage receptor affinity is low and 
stable binding to the epitopes on the antigen is crucial. A, In normal 
T-B-cell cooperation the 8 and the TH cells react to antigenic sites on 
the same molecule, thus a stable carrier-hapten bridge between the two 
specific cel ls is form ed. The hapte nic part of the immunogen is recog-
nized by the 8 cell result ing in signa l 1 to the 8 cell [29 ]; the ca rrier 
part of the immunogen is recognized by the TH cells which secrete 
helper factor( s), here designated signal 2 [29 ]. Macrophages also par-
ticipate in normal T-B cooperation, but are not depicted here. B, In 
abnormal T -8-cell cooperation the alloreactive TH cell reacts to a 
molecule, i.e. , alloantigen, which is physically separate from the mole-
cule the B cell reacts to. This alloreaction prov ides help, or signal 2, to 
all F, B cell s irrespective of their antibody specificity. Other than in 
normal T -B-cell cooperation, t.here is no TH ce ll that foc uses the 
epitopes to the 8 cel l. Hence the 8 cell has to interac t with the hapten 
all by itself. For an effective signal 1, mul tipoint binding between the 
epitopes on the hapten and the 8 cell is required. (1) If there is no 
hapten , no signal I delivered. The B cell cannot be triggered into 
optimal proliferation and lgG production. (2) Antigen is a globular 
protein, such as autologous thyroglobu lin (Tg) whose epitopes can only 
hind in a monova lent fashion to the lg recepto rs of the 8 cell. Mono-
valent binding is ineffective, because it is of low avid ity and doe~ not 
cross-l ink the lg receptors. (3 and 4) Antige n po~sesses repeating 
identical epitopes located on either a rigid backbone, such as DNA, or 
a cell surface; in addition, epitopes may be elect rically charged. T his 
allows for mu lt ipo int high-av idi ty-binding to and cross- linking of the 
lg receptor and thus provides an adequate signal 1. B cells are driven 
into clonal proliferation and max imal lgG sec retion. The difference 
between 1 and 2 on the one hand and 3 and 4 on the other hand 
GV H DISEASE AND GVH-LIKE DISEASES 117s 
class I and class II structures [18]. In such parent - F 1 
combinations t here is a sequential alloactivation first of donor 
TH cells and then T-allosuppressor/ killer (Ts1K) cells that cause 
t he suppressive pathological symptoms (Fig 1B) [18,20,24]. 
Thus, after a brief initial activation of Lyt 1 +2- donor TH cells, 
which resul ts in a transien t lymphoproliferation a nd B-cell 
stimulation in t he first week of GVHR, class !-specific Lyt 2+ 
donor T 51K cells are activated [20,25,28]. The detection of t hese 
F1-reactive T s;K effector cells in GVHR, mice was strictly 
confined, both in time and in t he parent - F, combinations 
being compared, to mice exhibiting t he suppressive pathologica l 
symptoms [18,20,25]. This established t hat F,-reactive donor 
T s;K ce lls are the effector cells causing t he hypoplastic GVH 
syndrome (Fig 1A ). 
Mechanism of Autoantibody Formation During GVHR 
There is general agreement t hat potentially autoreactive B 
lymp hocytes exist in healt hy individua ls, including ge netica lly 
norm al F 1 mice (5]. Although IJOrmally silent t hese F, B cells 
are able to secrete IgG autoantibodies upon adequate activation. 
During GVHR such an activation is delivered by t he donor's 
a lloreactive TH cells. Host (F1)-derived T cells a re not required 
for t he activation of t hose autoreactive B cells and, by contrast, 
counteract autoimmunization by t he GVHR [3,21] . The mech-
anism underlying t he GVHR-induced autoimmunization most 
likely is abnorma l T-B-cell cooperating, as illustrated in Fig 
2B. 
During normal T-B-cell cooperation for antibody product ion 
both TH and B cells react to antige nic sites on the same molecule 
(Fig 2A ). A stable carrier-hapten bridge is formed between the 
2 specific cells. The hapte nic part of t he immunogen is recog-
ni zed by t he B cell and delivers signal 1, whereas the carrier 
part is recogn ized by t he TH cell. The TH cell secretes helper 
factor(s) , here designated signal 2 [29]. Macrophages partici -
pate in t his activat ion process as an t igen-present ing cells. 
During abnormal T-B-cell cooperation (Fig 2B) F1 B cells 
receive signa l 1 by specific antigen, or hapten, and s ignal 2 (i .e., 
help), by a lloreactive TH cells of t he parental donor strain 
[5,29,30]. The TH cells are Lyt 1 +2- cells recogn izing a llogeneic 
class- II MHC ant icrens [26]. Antibodies resulting from abnor-
mal T-B-cell coope~ation in vivo belong main ly to t he IgG class 
[30,31] a nd have high affin ity [32]. 
The fi rst investigations of abnormal T-B-cell cooperation 
during GVHR were performed with non-self compounds as 
an tige n such as sheep red blood cells, or haptens such as 
t rini trophenyl and dini t rophenyl, coupled to special ca rrier 
molecu les. T hese studies demonstrated t hat a positive a ll oge-
neic effect, i.e ., a maximally enhanced lgG a nt ibody response, 
induced by a lloreactive TH ce lls [30,31], only occurred if the 
foreign antigen was present at t he onset of GVHR, thus pro-
viding signal 1 to the F1 B cells (16,31 ] (for rev1ew see (33]). 
Hence, in addition to signal 2 (a.llohelp), signal I (provided by 
epitopes on the antigen) is required for abnormal T-B-cell co-
operation to become optimally effective. 
During GVHR, a lloreactive donor TH cells provide signa l 2, 
or help, to t he F 1 B cells. This type of help is indiscriminatory 
because a ll F 1 B cells are semiallogeneic and can thus receive 
allohelp (Fig 2B). Neverthe less, t he resulting B-cell stimulation 
is a highly selective one. The reason for t his is t hat t he mere 
presence of a self-antigen is not enough to provide a n adequate 
signal 1 to the co rresponding autoreactive B cel l. Apparently, 
on ly t hose kinds of self-antige n dep icted in Fig 28.3, 2B.4 seem 
to supp ly an effective signa l 1. By t his reasoning we t ry to 
exp lai n the obse rvation t hat autoan t ibody formation in SLE-
like GVHD fa ils to be a random polyclonal event [29,33]. 
accounts for the phenomenon of selective lgG (auto)antibody formation 
found in SLE- like GVHD were autoant ibodies to DNA and ce ll -surface 
epitopes, but not to globular protein antigens, such as Tg, are formed. 
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GVHR-LIKE IMMUNOLOGICAL DISORDERS 
INDUCED BY MODIFIED SELF 
Concept of Pathogenesis 
The basic principles established for T cell alloreactivity, as 
operating in GVHR, might also operate in the ce llular patho-
ge nesis of GVHR-like diseases developing afte r exposure to an 
etiologic agent. GVHR-like cellular inte ractions may be stim-
ulated in auto logous or syngeneic systems provided cell -surface 
determinants of lymphohemopoietic ce lls and/or antigen-pre-
senting cells were modified by a given etiologic agent. These 
"altered-self' structures might trigger reactions by autologous 
T cells comparable to the reactions of parental stra in T cells 
toward the allogeneic structures on F , recipient cells. Thus, 
autologous or syngeneic TH cells may be preferent ially activated 
if a foreign ant igen X is recognized in association with class II 
MHC determinants [30,34,35]. In contrast, T 81 K cells may be 
preferentially activated if the same foreign antigen X is recog-
nized in association with class I MHC determinants [36]. Thus, 
depending on the T cell subpopulation activated, stimulatory 
or suppressive pathological symptoms may develop, as shown 
in Fig lA. Certa in drugs and viruses such as Epstein-Barr, 
cytomegalovirus, and rubella virus, are suspected to create such 
non-self structures because they have been found to be associ-
ated with various GVHR-like diseases in man . 
Drugs Known to Induce GVHR-Lihe Diseases 
An array of drugs have been reported to cause a variety of 
pathological symptoms out of the broad spectrum of GVHR-
like condi t ions shown in F ig l A. For example, the ant iconvul -
sant drug diphenylhydantoin (DPH, phenyto in, dil antin) has 
been reported to cause hypergammaglobulinemia, drug- induced 
SLE, a rt hritis, dermatit is, tox ic epidermal necrolysis, B-cell 
lymphomas, aplastic anemia, and hypogammaglobulinemia 
[14,37,38]. Furthermore, lymp hadenopathy, a feature of drug-
induced SLE, or thrombocytopenia and granulocytopenia de-
veloped during therapy of rheumatoid arthriti s with D-penici l-
lamine (39] or captopril , an antihyperte nsive drug- inhibiting 
angiotensin-I -coverting enzyme [ 40]. Hydralazine, another 
ant ihypertensive dru g, also causes drug- induced SLE [41] . 
Studies on the Pathogenic Mechanism of Drug-Induced 
GVHR-Lihe Symptoms 
The pop li teal lymp h node (PLN) assay, an establi shed 
method fo r measuring loca l GVH and host-ve rsus-graft (HVG) 
reactivity, was used to explore t he immunological effects of 
sensitizing drugs in vivo. It was found that subcutaneous injec-
tio n of DPH, D-penicillam ine, or captopri l into the hind fo ot 
pad of mice resu lted in a significant dose-dependent enlarge-
ment of t he draining PLN. T lymphocytes were required for 
tr iggering t his drug-induced enlargement. Congenitally a thymic 
nu/ nu recipients, i.e., T ce ll-deprived mice, fai led to react to 
the inoculation of t hese drugs, whereas their+ / nu counterparts 
readily did so [42] and unpublished resu lts). Al though T cell s 
were required for the DPH-induced PLN enla rgement the 
majority of t he proliferating cells in the PLN were not T cells 
[42,43]. These observations exclude that t he PLN reactions 
were caused by a direct mitogenic effect of DPH on B lympho-
cytes . Furthermore, DPH fail ed to exe rt nonspecific mitoge nic 
or comitogenic effects on lymphocytes in vivo and in vi t ro [43-
45] and unpubli shed resul ts). Subcutaneous injection of phe-
nobarbital, a drug t hat is pharmacologicall y and structurally 
related to DPH, but does not cause GVHR- like side effects , 
failed to induce PLN en largement [43). 
Additional studies revea led that subcutaneous inoculation of 
DPH induced a more t han 100-fold increase of IgG -secreting 
cells in the draining PLN as compared to the uninjected con-
tralate ral PLN [43]. Syngeneic spleen cell s which had been 
pretreated with DPH in vit ro also induced significant PLN 
enlargement. The spec ifi city of t he DPH-induced antibodies 
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TABLE 1. Selected reports on HLA associations with induced 
autoimmune phenomena 
Symptoms Induced by H LA association Reference 
Drug-induced SLE Hydralazine DR4 [41] 
Nephropathy D-penicillamine DR3 and B8 [51] 
Nephropathy Aurothiomalate DR3 and B8 [51) 
Selective lgA defi - Diphenylhydantoin A2 [54) 
ciency 
SLE-like autoanti- Spanish toxic oil DR3 and DR4 [53) 
bodies 
Severe scleroderma- Vinyl -chloride DR5 [52) 
like lesions 
remains to be tested. It is unlikely that the majority of these 
ant ibodies are directed against the small haptenic compound 
DPH. This assumption is consistent with the finding that 
DPH-specific antibodies were only rarely seen in patients sen-
sitized to the drug [44,46]. A DPH-spec ific lymphoproliferation 
in vitro was demonstrated in seve ral patients sensitized to the 
drug [38,45). 
The data on DPH is consistent with the concept that the 
parent molecule, or its metabolites, can render membrane struc-
tures of potentially stimulatory cells, such as dendri t ic cells 
and B lymphocytes, "non-self'. T lymphocytes would then 
recognize these a ltered membrane determinants in conjunction 
with autologous MHC structures and respond in a GVHR-like 
manner, resulting in the development of the respective immu-
nological les ions. 
The proposed immunopathogeneses induced by an etiologic 
agent may a lso be relevant for the mechanisms of mercury 
chloride (HgC]z)-induced lesions in rats [47,48]. Autoimmune 
glomerulonephritis, splenomegaly, antinuclear, and ant i-DNA 
ant ibodies were observed in HgCh-susceptible strains, but not 
in strains carrying other MHC haplotypes. HgC12 -induced B-
cell activation was observed, both in vivo and in vitro, on ly in 
the susceptible strain. Interestingly, the B-cell activation in 
vitro wasT-cell-dependent [47]. 
No PLN enla rgement was found in several mouse strains 
which had been t reated with hydralazine or methyldopa, drugs 
that are well known to induce SLE and autoimmune hemolytic 
anemia, respectively [49,50]. The pathogenic mechanisms by 
which these drugs induce the immunological injuries remain to 
be evaluated. · 
Interestingly, in human, a high association has been reported 
between certain genetic factors and severa l etiologic agents 
causing GVHR-like symptoms (Table I). Thus, here is a pre-
ponderance of both HLA-DR4 positivity and slow acetylation 
in patients with hydralazine-induced SLE [ 41). Moreover, sig-
nificant assoc iations have been found between gold- or D-
penicillamine-induced glomerular nephropathy and HLA- DR3 
and -B8 [51], between vinyl-chloride-induced severe sclero-
derma- like lesions and DRS [52], and between DR3 and DR4 
and SLE-like autoantibodies after ingestion of the Spanish 
tox ic oil [53]. DPH-induced lgA-deficiency is associated with 
HLA-2 (54] . 
CONCLUSIONS 
The genetic and cellular requirements for induction by 
GVHR of broad spectrum immunological disorders on the one 
hand and the GVHR-like features induced by DPH [49,50] and 
HgClz [54,55] on the other hand are considered relevant for the 
pathogenesis that may underly some of the human GVHR-Iike 
diseases associated with certain HLA alleles. A given etiologic 
agent is assumed to induce an antigenic site X on cell-surface 
dete rminants ("altered-self'). In a susceptible individual au-
tologous T lymphocytes might recognize and respond to these 
antigenic sites akin to the way parental strain T lymphocytse 
recognize and respond to allogeneic MHC structures ofF, celL 
in the GVHR model [33]. Thus, TH cells are preferent ially 
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activated if the antigenic s ite X is m a inly associated or seen 
· togethe r wi t h class-II HLA structures. In contrast, TS/ K cell s 
are prefere n t ia lly activated if t he antigenic s ite X is m a inly 
associated or seen togethe r with cl ass- I HLA structures. Cor-
respondingly, immunologica l di sorde rs co ns isting of stimu la-
tory or suppressive GVHR-like symptoms would e n sue as illus-
t rated in Fig 1. Certa inly, a numbe r of othe r immunolouica l 
a nd nonimmunologica l factors suc h as ly mphokines, sex h o r-
mones, a nd m etabolic pathways of a given etio logic agen t, a lso 
co n tribute to t h e complex processes eventua lly resul t in o- in 
immunopathological lesio ns. Therefore, in most cases theb in -
duction of disease by a n etio logic agen t depends on t he presence 
of suscep t ibil ity a ll e les at a number of differen t gen etic loci. 
Assessment of t he pathogenic pathways by which ide n ti fi ed 
etio logic agents induce immunologica l diseases s hould increase 
our knowledge of t he etiopathology of the sa me diseases deve l-
oping s p onta n eous ly . These investigatio ns m ay he lp to e la bo-
rate m ethods to eve n t u a lly prevent a nd/or cure those diseases. 
We are obli ged to our colleaf,rues Drs. A. G. Rolink, E. H. van E lven , 
S . T . Pals, and T. Radaszkiewicz whose in te llectua l contr ibutions and 
dedicated work made t hi s publication possible. 
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